Loading…
RenovoRx, Inc. is projected to rise to $1.30 by 2027, a +23% move from its current price of $1.06. RNXT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.03 | $1.06 | $1.10 | +0.08% |
| Aug 6 | $1.01 | $1.06 | $1.11 | +0.16% |
| Aug 7 | $1.00 | $1.06 | $1.12 | +0.25% |
| Aug 8 | $0.996 | $1.06 | $1.14 | +0.33% |
| Aug 9 | $0.9892 | $1.06 | $1.15 | +0.41% |
| Aug 10 | $0.9831 | $1.07 | $1.15 | +0.50% |
| Aug 11 | $0.9776 | $1.07 | $1.16 | +0.58% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9776 | $1.07 | $1.16 | +0.58% |
| Week 2 | $0.9485 | $1.07 | $1.21 | +1.16% |
| Week 3 | $0.9281 | $1.08 | $1.25 | +1.75% |
| Week 4 | $0.912 | $1.08 | $1.29 | +2.33% |
| Week 5 | $0.8987 | $1.09 | $1.32 | +2.93% |
| Week 6 | $0.8873 | $1.10 | $1.36 | +3.52% |
| Week 7 | $0.8774 | $1.10 | $1.39 | +4.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted combination therapies to improve therapeutic outcomes for cancer patients.
Its lead product candidate is gemcitabine, which is provided through RenovoCath and is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
The company was founded in 2009 and is headquartered in Mountain View, California.
RNXT is a healthcare stock with a current price of $0.9651 and a market cap of $43.53M. Its rank is 4428 among traded securities.
Technically, the sentiment is BULLISH, with RSI14 at 60. The SMA50 is $0.8963 and the SMA200 is $0.9476, with a support level at $0.844 and a resistance at $0.98.
The 30-day price range spans from $0.7668 to $1.21, and the stock shows an annualized volatility of 70%.
A major floor 26.1% below — a decisive break under it would weaken the trend.
The nearest floor, 19.8% below — buyers have tended to step in here.
Resistance now sits 7.5% below — it may act as fresh support.
A major ceiling 9.4% above — clearing it would confirm fresh momentum.
Key RNXT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNXT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9338 | Buy | $0.9286 | Buy |
| MA 10 | $0.8997 | Buy | $0.9133 | Buy |
| MA 20 | $0.9006 | Buy | $0.9067 | Buy |
| MA 50 | $0.9054 | Buy | $0.9066 | Buy |
| MA 100 | $0.9214 | Buy | $0.9191 | Buy |
| MA 200 | $0.9418 | Buy | $0.9595 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.42 | Neutral |
| Stoch RSI (14) | 86.65 | Sell |
| CCI (20) | 117.89 | Buy |
| Williams %R (14) | -6.09 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 11.40 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 93.91 | Sell |
| TRIX (15) | -0.06 | Sell |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 62.76 | Neutral |
| Momentum (10) | 0.09 | Buy |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 0.94 | Buy |
| ADX (14) | 10.09 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture indicates a bullish tilt, supported by RSI of 60. This aligns with the stock trading near its short- to mid-term moving averages, with SMA50 at $0.8963 and SMA200 at $0.9476.
Near-term technical levels place support at $0.844 and resistance at $0.98, framing a 30-day price range between $0.7668 and $1.21.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.783 | $1.06 | $1.42 | 0% | Neutral | |
| $1.02 | $1.30 | $1.77 | +23% | Bullish | |
| $1.29 | $1.71 | $2.43 | +61% | Bullish | |
| $1.34 | $1.83 | $2.68 | +72% | Bullish | |
| $1.35 | $1.89 | $2.85 | +78% | Bullish | |
| $1.33 | $1.89 | $2.93 | +79% | Bullish | |
| $1.30 | $1.90 | $3.01 | +79% | Bullish | |
| $1.61 | $2.40 | $3.88 | +127% | Bullish | |
| $1.82 | $2.76 | $4.54 | +160% | Bullish | |
| $1.85 | $2.86 | $4.78 | +170% | Bullish | |
| $2.47 | $4.17 | $7.49 | +294% | Bullish | |
| $3.44 | $6.76 | $13.43 | +538% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.783 | $1.06 | $1.29 | +0.00% |
| September 2026 | $0.9458 | $1.12 | $1.38 | +6.10% |
| October 2026 | $0.953 | $1.14 | $1.42 | +1.61% |
| November 2026 | $0.916 | $1.11 | $1.39 | -3.22% |
| December 2026 | $0.9218 | $1.12 | $1.42 | +1.25% |
Click any year to see its month-by-month RNXT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RNXT to range from $0.783 to $1.42 through 2026. The $1.06 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The RNXT price prediction for 2027 points to an average of $1.30 (low $1.02, high $1.77) — a potential gain of +23% on today's $1.06. Momentum favours further upside here.
In 2028, RNXT is projected to trade between $1.29 and $2.43, averaging $1.71 — a potential gain of +61% from today's $1.06. That is up +31% on the projected 2027 average. Buyers look set to stay in control over this stretch.
RenovoRx, Inc.'s 2029 outlook centres on $1.83, within a $1.34 to $2.68 range. That is up +7% on the projected 2028 average. That marks a +72% change versus current levels. Momentum favours further upside here.
By 2030, RNXT could reach as high as $2.85, with a base case around $1.89 and support toward $1.35 — roughly +78% from $1.06. Buyers look set to stay in control over this stretch.
Expect RNXT to range from $1.33 to $2.93 through 2031. The $1.89 average target implies a +79% move from current prices. That is up 0% on the projected 2030 average. Momentum favours further upside here.
The RNXT price prediction for 2032 points to an average of $1.90 (low $1.30, high $3.01) — a potential gain of +79% on today's $1.06. Buyers look set to stay in control over this stretch.
In 2033, RNXT is projected to trade between $1.61 and $3.88, averaging $2.40 — a potential gain of +127% from today's $1.06. That is up +26% on the projected 2032 average. Momentum favours further upside here.
RenovoRx, Inc.'s 2034 outlook centres on $2.76, within a $1.82 to $4.54 range. That is up +15% on the projected 2033 average. That marks a +160% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, RNXT could reach as high as $4.78, with a base case around $2.86 and support toward $1.85 — roughly +170% from $1.06. Momentum favours further upside here.
Expect RNXT to range from $2.47 to $7.49 through 2040. The $4.17 average target implies a +294% move from current prices. That is up +46% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The RNXT price prediction for 2050 points to an average of $6.76 (low $3.44, high $13.43) — a potential gain of +538% on today's $1.06. Momentum favours further upside here.
Investing $1,000 in RNXT today (≈ 943.396226 RNXT) could be worth
$6,379.72
+$5,379.72 (+538%) by 2050 · US Dollar
Based on the average projected RNXT price of $6.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNXTwould be worth at today's price.
$1,000 invested in RNXT on Jul 31, 2025 (≈ 806.451607 RNXT) would be worth
$854.84
-$145.16 (-14.5%) today · 0.85× · US Dollar
Based on a RNXT entry price of $1.24 vs. today's $1.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.865 | $1,225.43 | +22.5% |
| 1 month ago | $0.955 | $1,109.95 | +11.0% |
| 3 months ago | $0.883 | $1,200.45 | +20.0% |
| 6 months ago | $1.02 | $1,039.22 | +3.9% |
| 1 year ago | $1.24 | $854.84 | -14.5% |
| All time (4.9y) ago | $7.26 | $146.01 | -85.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNXT forecast.
Our base-case forecast reaches $2.10 around 2033.
Implied market cap at $2.10: $94.71M
The multi-year forecast shows a rising average price trajectory. In 2026 the min is $0.783, the avg is $0.9651, and the max is $1.34.
From 2027 onward, the avg prices move higher: $1.27 (2027), $1.69 (2028), $1.83 (2029), $1.88 (2030), $1.91 (2031), and $1.99 (2032). The forecast continues with $2.56 (2033), $2.95 (2034), and $3.09 (2035).
By 2040 the avg price is $4.69 with a max of $8.60, and by 2050 the avg reaches $7.79 with a max of $15.87. Corresponding ROIs rise from 31.2 (2027) through 74.8 (2028), 89.6 (2029), 94.8 (2030), 97.9 (2031), 106 (2032), 165.6 (2033), 206 (2034), 219.9 (2035), 385.7 (2040), and 706.8 (2050). Sentiment is bullish across the forecast years, with 2026 labeled as Neutral.
Tap a question to reveal the answer.
2030 avg $1.88; min $1.33; max $2.88; ROI 94.8; sentiment bullish.
The long-term forecast shows bullish sentiment from 2027 onward with ROIs up to 706.8 by 2050 and a 2050 avg price of $7.79 (max $15.87). These are estimates and not guarantees.
Yes, the 2040 max is $8.60 and the 2040 avg is $4.69, with 2050 max $15.87 and avg $7.79, indicating that hitting or exceeding $5 is possible within the forecast horizon.
Current price $0.9651; Market cap $43.53M.
2026 min $0.783; avg $0.9651; max $1.34; sentiment Neutral.
RenovoRx, Inc. Community Discussion
0Share your RenovoRx, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.